Mirabegron, the first in a new class of beta-3 adrenoceptor agonists to treat patients with overactive bladder syndrome (OAB), significantly reduces the incidence of urinary incontinence and micturition, according to results from 2 phase 3 studies presented here at the European Association of Urology 26th Annual Congress.
At once-daily doses of 50 and 100 mg, mirabegron was superior to placebo in the treatment of OAB, was well tolerated in the study populations, and demonstrated the promising therapeutic potential of this new class of drugs in the treatment of this syndrome.
Of particular interest with mirabegron, as a first-in-class drug, are drug-related adverse events. "There were no significant cardiovascular events in the mirabegron group. Overall incidence of hypertension was similar across groups, and there was no effect on the [electrocardiogram] cycle QT interval. That's important because certain drugs can affect this and lead to cardiac risks
source:medscape
Thanks a lot mam for giving us more info.I checked in the site and found that to be very useful.We are a group of medicos from India running this blog to enlighten the medicos with recently approved FDA drugs and recent medical advances.
ReplyDeleteThanks for the help :)